Meeting Highlights from American Diabetes Association 79th Scientific Sessions

June 7-11, 2019
Moscone Convention Center San Francisco, CA

This annual five-day professional program attracted more than 11,000 medical practitioners and researchers who convened to share the latest data on the diagnosis, treatment, and advances in clinical care relevant to preventing, slowing/reversing progression, and treating diabetes and associated complications.

Presentations have been orgtanized into eight themed areas include acute and chronic complications, lifestyle and behavioral medicine, clinical therapeutics,integrated physiology/obesity, insluin action (metabolism), insulin secretion, genetics and epidemiology, immunology/transplantation

Progress in Precision Medicine Elevates Diabetes Care

The evolving landscape of precision medicine in clinical diabetes management offers great promise in individualizing treatment and categorizing patient care by susceptibility to diabetes related diseases and responsiveness to treatment. The significance of the research and application of findings was addressed by Alice YY Cheng, MD, FRCPC, associate professor of medicine the University of Toronto, Canada, during symposium planned jointly by the ADA and the American Society of Nephrology.1

“Are we actually at the point of perfect precision medicine? Of course not. Oncology is far further ahead than we are, but I think certainly in the diabetes space, there’s a big push for that. In the diabetic kidney disease (DKD) space, there are consortiums that have been developed and various symposia. So there’s a great interest in going there, and I think that’s certainly where the future lies,” Dr. Cheng said.

The biggest challenges to optimizing individualized care involve access to data, including healthy human tissue, advanced technology capable of processing volumes of data, better clinical trial design, coordination between research entities, regulatory agencies, and insurance players.

Dr. Cheng cited three international consortiums—Biomarker Enterprise to Attack Diabetic Kidney Disease (BEAt-DKD), Diabetes in Nephrology and Other Microvascular Complications (DYNAMO), and Transformative Research in Diabetic Nephropathy (TRIDENT)—that are pooling resources to gather the data necessary for the development of precision diagnostics and treatment advances.2-4

We want to capture different diagnostics, not just the known elements that are currently measured, but to include environmental influence and patient preferences, in order to arrive at  appropriate medication plan for the right patient, she said.

EndorineWeb selected four compelling presentations to share from the among the more than 180 sessions, reflecting state-of-the art advances in prevention and treatment of type 2 diabetes:

  • The potential of supplemental Vitamin D to slow or even reverse progression of prediabetes to frank diabete.
  • Targeting Immunity with a variety of therapies to arrest progression of type 1 diabetes: TrialNet results
  • A series of PIONEER trials—the first head-to-head treatment interventions in patients with type 2 diabetes—provide data in support of adding the first oral GLP-1 (semaglutide) to achieve better outcomes regarding weight loss and glucose control (HbA1c).
  • The focus of diabetes management requires vigilance with regard to increased risks of cardiiovascular disease kidney disease in patients with type 1 diabetes. Results of the CRedence and Carmelina Studies are presented as part of the 2019 Edwin Bierman Award lecture, "Linking Kideny and Cardiovacular Complications—Impact on Prognosis and Treatment" presented by this year's honoree, Peter Rossing, MD, DSMc, who leads Complications Research and is the Chief Physician at Steno Diabetes Center in Copenhagen, Denmark.
Last updated on
First Article From This Meeting:
Oral Semaglutide Proves Most Effective in Patients with Type 2 Diabetes
close X
SHOW MAIN MENU
SHOW SUB MENU